Elekta Business Model Canvas

Elekta depends on specialists supplying high-grade parts for linear accelerators and Gamma Knife systems, sourcing magnets, vacuum systems, and radiation‑shielding materials; in 2024 supply‑chain costs rose ~6% and supplier consolidation reduced lead‑time variability by 18% in key components. Maintaining resilient contracts and dual sourcing helped keep 2024 production on target for SEK 15.2bn revenue in oncology systems.

Developing and updating oncology information systems is a core activity supporting clinical workflows, with Elekta reporting ~15% annual growth in software revenue and 2024 software ARR around SEK 1.2bn; teams build interfaces linking diagnostic imaging to treatment delivery to cut planning time by ~20%.

Software engineering prioritizes interoperability (DICOM, HL7 FHIR), data security (ISO 27001), and cloud SaaS shifts—Elekta’s cloud adoption rose to ~30% of new contracts in 2024, improving upgrade velocity and recurring revenue.

Elekta focuses R&D and product engineering on MR‑Linac and Gamma Knife precision, SEK 2.3bn R&D (2024), shifting 30–35% to ML workflow automation by end‑2025; service & quality maintain >95% device uptime with SEK 1.2bn product quality spend and SEK 12.4bn service revenue (2024), remote/predictive coverage ~40% cutting downtime ~30%.

Elekta operates modern manufacturing plants and R&D centers across Europe, North America and Asia, accounting for roughly 65% of capex in 2024 (≈SEK 650m) to support high‑precision engineering and software testing. These facilities house specialized CNC, robotics and clinical‑trial labs, enabling scalable production to meet global demand—group revenue was SEK 13.2bn in FY2024, with manufacturing capacity expanded 18% vs 2022.

Elekta’s key resources: 3,200+ granted patents & 1,400 pending (2025); ~3,500 specialists; FY2024 R&D SEK 1.6bn; manufacturing capex SEK ~650m (2024); FY2024 revenue SEK 13.2bn, software/services SEK 6.1bn (26%); service revenue SEK 4.2bn (35%); 120+ countries, ~48h median onsite response (major markets), ~90% uptime SLA.

Elekta’s Adaptive and Real-Time Guided Treatment lets clinicians view tumors during radiation using systems like the Elekta Unity MRI‑guided linac, enabling on‑table adjustments for anatomy or position shifts and reducing margins; clinical studies show MRI‑guided adaptive therapy can cut planning target volume by ~20–40% and Elekta reported Unity installed base exceeding 60 systems by end‑2024, driving higher treatment precision and potential revenue uplifts.

Elekta’s precision radiotherapy (SRS/SBRT) and MRI‑guided linac boost local control up to 15% and cut grade‑3+ toxicities ~30%, with advanced systems at 28% of 2025 revenue and Unity installs >60 by end‑2024; workflow integration cuts admin time ~30%, raises throughput 15–25%, and saves $200–$450 per patient; service uptime >95%, downtime −40%, 20,000+ clinician hours (2024).

The Elekta Care Learning program delivers in-person and digital training to clinicians and physicists, with Elekta reporting >25,000 course completions in 2024 and a 92% satisfaction rate, ensuring clinical teams use systems optimally and improving outcomes (e.g., protocol adherence up to +18%). This education strengthens brand loyalty, reduces device downtime, and supports recurring service revenue—Elekta cited service revenue of SEK 6.1bn in FY2024.

Elekta builds long-term ties via multi-year SLAs (38% recurring revenue, 99.5% target uptime), Lighthouse partnerships (60+ sites; €45m collaborative R&D in 2024), training (25,000+ completions, 92% satisfaction) and digital self-service (65% digitalized service, 18h response; SEK 2.1bn software recurring revenue, SEK 10.2bn total service revenue in 2024).

Participation in major congresses such as ASTRO (US) and ESTRO (EU) lets Elekta showcase product launches and clinical data; at ASTRO 2024 Elekta-supported abstracts accounted for ~18% of session presentations on MR-guided and adaptive RT, driving direct leads—trade shows generated ~€24m in FY2024 marketing-influenced order pipeline and sustained brand visibility across 70+ countries.

Elekta sells mainly via a global direct sales force (62% of 2024 revenue; >€1.3bn radiotherapy order book) plus distributors in 60+ countries (18% of 2024 revenue ~SEK 2.6bn); tenders account for ~40% of sales (win rate ~18%, avg oncology order >$3.5M); digital channels handled 38% of service interactions and drove SEK 3.1bn software revenue (2024).

Academic and research universities use Elekta systems for patient care, clinical trials, and teaching, requiring open architectures for data extraction and integration with experimental protocols; in 2024 university-linked clinical trials accounted for ~22% of radiotherapy device-related studies globally (ClinicalTrials.gov).

Hospitals (65% spend; centers treat 1,200–2,500 pts/yr), specialized cancer centers (MR‑Linac ~420 units in 2024; Gamma Knife rev ≈USD220M), universities (22% of radiotherapy trials), governments (70% LMIC gap per WHO 2024), neurosurgery clinics (140,000 SRS procedures in 2024).

Maintaining Elekta’s direct sales force and attending international medical conferences costs hundreds of millions annually; Elekta reported sales and marketing expenses of SEK 3.2 billion (≈USD 300M) in FY2024, reflecting travel, booth presence, and field reps. Marketing also funds clinical evidence and training—clinical study budgets and educational programs often amount to 5–10% of marketing spend—to defend and grow market share in a competitive global radiotherapy market.

Elekta’s cost structure is R&D-heavy (SEK 1.1bn, FY2024) and manufacturing/service intensive (manufacturing/distribution SEK 4.1bn; service revenue SEK 9.2bn), with S&M SEK 3.2bn and compliance costs ~8–12% of revenue; recalls/fines risk tens of millions USD.

Post-warranty service agreements generate steady, high-margin revenue for Elekta—services (maintenance, emergency repairs, upgrades) represented about 28% of 2024 service revenue, with gross margins typically 40–60% and multi-year contracts averaging 5–7 years; this recurring segment is less cyclical than capital sales, helping stabilize cash flow when system orders dip (Elekta reported services revenue of SEK 6.2bn in 2024).

Elekta’s revenue mix: capital equipment (SEK 12.4bn FY2024) drives large one-time sales; services (SEK 6.2bn 2024) and consumables (18–22% of parts/service revenue) plus software (SEK 2.1bn 2024; ~48% recurring by Q3 2025) shift mix toward recurring income, with service backlog SEK 8.1bn end‑2025.